SWShu-Ling Wu

Shu-Ling Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shu-Ling Wu has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Ge Shen

    Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China

    4 shared publications
  • Ruyu Liu

    Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China

    4 shared publications
  • Yao Lu

    Department of Hepatology Division 2 Beijing Ditan Hospital Capital Medical University Beijing China

    4 shared publications
  • Yao Xie

    Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University

    4 shared publications
  • Hongxiao Hao

    Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China

    3 shared publications
  • Leiping Hu

    Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China

    3 shared publications

Latest Publications

  • Open Access

    Rethinking Language Proficiency: Commentary on Hulstijn (2024)

    by Lourdes Ortega, Shu-Ling Wu

    We enjoyed reading Jan Hustijn’s update of his Basic Language Cognition (BLC) theory in the pages of Languages (Hulstijn, 2024), and we are honored to provide a commentary here. Researchers, language learners, and educators hold varying definitions and understandings of language proficiency. Innovative work that helps researchers in the field rethink proficiency is therefore of utmost importance. Hulstijn’s BLC theory offers a clear, well-motivated, and comprehensive framework for investigating what language proficiency may be, what ceilings there may be in what can be attained, and what causes there may be for attainment differences. Hulstijn tells us that BLC rests on a metatheory (i.e., a foundation of assumptions) of language and language learning grounded in two areas familiar to most scholars in second language acquisition (SLA): usage-based linguistics and complex systems. He offers BLC as a theory, that is, a tool to empirically investigate the causation and development of a phenomenon, in this case, proficiency, through a well-articulated research program. In this commentary, we highlight some aspects of the updated BLC theory that we find most useful. Following the Popperian spirit embraced by Hulstijn, we also introduce some critical probes subjects for refinements that may benefit BLC theory in the future.


  • Open Access

    Postpartum hepatitis and host immunity in pregnant women with chronic HBV infection

    by Lu Zhang, Tingting Jiang, Ying Yang, Wen Deng, Huihui Lu, Shiyu Wang, Ruyu Liu, Min Chang, Shuling Wu, Yuanjiao Gao, et al.

    In order to develop immune tolerant to the fetal, maternal immune system will have some modification comparing to the time before pregnancy. Immune tolerance starts and develops at the maternal placental interface. In innate immunity, decidual natural killer (dNK) cells, macrophages and dendritic cells play a key role in immue tolerance. In adaptive immunity, a moderate increase of number and immune inhibition function of regulatory T cells (Treg) are essential for immune tolerance. The trophoblast cells and immune cells expressing indoleamine 2,3-dioxygenase (IDO), the trophoblast cells expressing HLA-G, and Th1/Th2 shifting to Th2 dominant and Th17/Treg shifting to Treg domiant are in favor of maternal fetal immune tolerance. Steroids (estrogen and progesterone) and human chorionic gonadotropin (HCG) also participate in immune tolerance by inducing Treg cells or upregulating immunosuppressive cytokines. Most of the patients with chronic HBV infection are in the “HBV immune tolerance period” before pregnancy, and the liver disease is relatively stable during pregnancy. In chronic HBV infection women, after delivery, the relative immunosuppression in vivo is reversed, and Th1 is dominant in Th1/Th2 and Th17 is dominant in Th17/Treg balance. After delivery, the number of Treg decrease and NK cells increase in quantity and cytotoxicity in peripheral blood. Liver NK cells may cause liver inflammation through a non-antigen specific mechanism. After delivery, the number of CD8+ T cells will increase and HBV specific T cell response recovers from the disfunction in pregnancy. Under the background of postpartum inflammation, the rapid decrease of cortisol after delivery, and especially the enhancement of HBV specific T cell response induced by HBV DNA and cytokines, are the main reasons for postpartum hepatitis. HBeAg positive, especially HBeAg3-5Log10IU/ml are risk factors for postpartum hepatitis. Antiviral treatment in late pregnancy can reduce the incidence of mother to child transmission (MTCT) in chronic HBV infection women. Chronic HBV infection women have hepatitis both during pregnancy and more often in 12 weeks postpartum. It is generally agreed that postpartum hepatitis is mild symptoms and self-limited. Delaying drug withdrawal to 48 weeks can increase the seroconversion rate of HBeAg in delivery women with elevated alanine aminotransferase (ALT) in pregnancy.


  • Hepatitis B core‐related antigen serum levels are associated with significant liver fibrosis in treatment‐naive chronic HBV infection patients

    by Ruyu Liu, Minghui Li, Yao Lu, Lu Zhang, Ge Shen, Shuling Wu, Min Chang, Hongxiao Hao, Leiping Hu, Yuanjiao Gao, et al.

    Several hepatitis B virus (HBV) serum markers have been identified as risk factors for liver fibrosis in patients with chronic HBV infection, and several noninvasive fibrosis tests based on serum indexes are now used to identify the severity of liver fibrosis. We aimed to identify the relationship between hepatitis B core-related antigen (HBcrAg) serum levels and liver fibrosis in treatment-naive chronic HBV infection patients. A total of 246 treatment-naive chronic HBV infection patients were enrolled in this study. All of the patients underwent liver biopsies at baseline. Using the METAVIR fibrosis stages, there were 15, 140, 50, 26 and 15 patients in the F0, F1, F2, F3 and F4 stages (METAVIR scoring system), respectively. The biochemical, serological and virological parameters were measured using standard laboratory procedures. The HBcrAg serum levels of the patients were examined via ELISA. HBcrAg serum levels of F2, F3 and F4 stage patients were significantly higher than those of nonsignificant liver fibrosis patients (METAVIR F0-F1), but there were no significant differences among F2, F3 and F4 stage patients. Serum HBcrAg (OR, 2.18; 95% confidence interval [CI], 1.51-3.16), albumin (ALB) (OR, 0.60; 95% CI, 0.41-0.87), prothrombin activity (PTA) (OR, 0.58; 95% CI, 0.40-0.83) and platelet (PLT) counts (OR, 0.38; 95% CI, 0.25-0.57) were associated with significant liver fibrosis (METAVIR F2-F4). The serum HBcrAg value enabled the correct identification of patients with significant fibrosis, with an area under the receiver operating characteristic curve of 0.81 (95% CI, 0.75-0.88). The APRI, FIB-4 index and ALBI score can identify significant liver fibrosis with an area under the ROC curve of 0.74 (95% CI, 0.66-0.81), 0.73 (95% CI, 0.65-0.80) and 0.63 (95% CI, 0.55-0.72), respectively. Compared with these three indexes, the accuracy rate of diagnosis of significant fibrosis based on HBcrAg was higher than that of the FIB-4 index (p = 0.0479) and ALBI score (p = 0.0030). HBcrAg, ALB, PTA serum levels and PLT counts were associated with significant liver fibrosis in treatment-naive chronic HBV infection patients. HBcrAg serum levels enabled the correct identification of patients with significant fibrosis (METAVIR F2-F4), and HBcrAg was more effective than the FIB-4 index and ALBI score.


  • ELICITED IMITATION AS A MEASURE OF L2 PROFICIENCY

    by Shu-Ling Wu, Yee Pin Tio, Lourdes Ortega

    Elicited imitation (EI), a short-cut measure of global proficiency in second language (L2) research, requires participants to listen to sentences and repeat them as closely as possible. To support instrument sharing and assessment of L2 proficiency for longitudinal and crosslinguistic research, we created a parallel form of an EI task (EIT) for L2 English originally developed by the third author and colleagues and investigated the reliability and validity of the original and new forms. Eighty-two participants completed the two EITs, an oral narrative task, and a self-diagnostic survey. Both forms exhibited high reliability and good alignment with external criterion measures. Both distinguished well among four proficiency levels in the sample. Further, participants’ perception of EI difficulty aligned well with their EI scores. We suggest some improvements to boost forms equivalence and discuss new insights about the nature of EI as reconstructive, integrative, modality independent, and with indirect links to communicative abilities. Our study seeks to make this English EIT instrument widely useful to the L2 research community.


  • Open Access

    AST and HBeAg Level Can Help to Distinguish Non-Minimal Liver Inflammation in Persistently Normal Alanine Aminotransferase of Chronic HBV Infection

    by Lu Zhang, Ming Hui Li, Wei Yi, Yao Lu, Shu-Ling Wu Wu, Hong-Xiao Hao, Yuan-Jiao Gao, Hui-Hui Lu, Qiqi Chen, Ge Shen, et al.

    Objectives: The current study aimed to investigate the characteristics of HBV serum markers (HBsAg, HBeAg), biochemical indicators, HBV DNA, and the age to distinguish minimal from non-minimal liver histological inflammation group in HBeAg-positive chronic HBV-infected patients with ALT≤ 1ULN (40U/L). Methods: The HBeAg-positive patients with treatment-naïve hospitalized at Ditan hospital from January 2008 to January 2017 are investigated. Patients were separated into two groups of minimal and non-minimal (mild and moderate) histological inflammation group by liver biopsy specimens. Data were analyzed using the SPSS package. Results: There were both positive (age, ALT, and AST) and negative correlation factors (serum HBsAg, HBeAg, or HBV DNA quantitation) to the liver inflammation grades. Multivariate regression analysis indicated that HBeAg (P < 0.001, b = -0.554, Exp (B) = 0.575) and AST (P = 0.003, b = 0.074, Exp (B) = 1.077) were independent influential factors. The cutoff values of HBeAg and AST were separately 2.85 Log10S/CO (AUC0.724, Sensitivity64%, Specificity79%), 28U/L (AUC0.726, Sensitivity68%, Specificity 78%) to distinguish Minimal from Non-minimal liver histological inflammation in chronic HBV-infected patients with ALT ≤ 1 ULN (40U/L). Conclusions: In total, 31.34% (115/367) of patients with chronic HBV infection who had non-minimal (mild and moderate) liver histological inflammation reached the required inflammation levels for antiviral treatment in HBeAg-positive patients with persistently normal ALT. HBeAg (cutoff < 2.85 Log10S/CO) and AST (cutoff > 28 U/L) were the independent influential factors of predicting non-minimal liver inflammation with ALT ≤ 1 ULN (40U/L).


  • Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy

    by Ruyu Liu, Jiang Guo, Yao Lu, Lu Zhang, Ge Shen, Shuling Wu, Mi Chang, Leiping Hu, Hongxiao Hao, Minghui Li, et al.

    According to guidelines, antiviral therapy for adults with immune-active chronic hepatitis B (CHB) should be adopted to decrease the risk of liver-related complications. Fibrosis assessment during antiviral treatment is a key step in antiviral therapy evaluation. Liver biopsy is the gold standard for assessing the degree of liver necroinflammation and fibrosis. However, because of its cost and the risk of life-threatening complications, performing a liver biopsy more than once after long-term effective treatment is difficult. In this study, we aimed to evaluate changes in liver fibrosis during 5 years of entecavir (ETV) treatment using noninvasive fibrosis markers in hepatitis B e-antigen (HBeAg)-negative treatment-naive CHB patients who require antiviral therapy. A total of 303 HBeAg-negative treatment-naive patients were enrolled in this study. Liver biopsy was performed before initiation of antiviral therapy. The diagnosis of CHB was made according to Chinese guidelines for the management of CHB. Patients requiring antiviral therapy (liver fibrosis stage ≥ F2, METAVIR scoring system) were treated with ETV for at least 5 years. These patients were followed up at 6-month intervals. A clinical and virological evaluation was performed at baseline and again at 12, 24, 36, 48, and 60 months during ETV treatment. Aspartate Aminotransferase to Platelet Ratio Index (APRI) and Fibrosis-4 (FIB-4) index were used to assess dynamic changes in liver fibrosis in HBeAg-negative CHB patients after 1, 2, 3, 4, and 5 years of ETV treatment. All enrolled patients underwent liver biopsy at baseline. Using the METAVIR fibrosis stages, there were 107, 125, 54, and 17 patients in F1, F2, F3, and F4 stages, respectively. The APRI and FIB-4 indexes enabled the correct identification of patients with severe fibrosis (METAVIR F3–F4), with an area under the receiver operating characteristic curve of 0.77 (95% confidence interval [CI] 0.72–0.83) and 0.76 (95% CI 0.70–0.82), respectively. The APRI values decreased significantly in F2 and F3 patients after 1 year of ETV therapy (P < 0.01). However, for F4 patients, APRI values decreased significantly at year 3 (P < 0.05). The FIB-4 values of F2, F3, and F4 patients who received ETV treatment were significantly decreased after 1, 3, and 5 years of ETV therapy, respectively (P < 0.05). APRI and FIB-4 values decreased significantly during 5-year ETV treatment in HBeAg-negative CHB patients, indicating that these noninvasive fibrosis tests might be useful for monitoring improvement in liver fibrosis and assessing treatment efficacy during long-term ETV treatment.


  • 完成体和经历体 “过” 之语法教学:以美国常见的三套教材为例

    by Shu-Ling Wu, 马 玉汴

    摘要: 完成体和经历体 “过” 是汉语语法里用来表示事件内部时间结构的重要工具,两者在语法结构和功能上有许多差异。然而当前的主流教材在初级和中级课本的编写上,多半只着重教授经历体 “过” 的用法,忽视完成体 “过” 的介绍,造成课堂语法教学无法反映语言现实的情况。本文针对两种 “过” 的教学进行了一系列研究,首先讨论两种 “过” 的区别,再综述教学语法的基本原则以及体貌标记的习得研究,然后具体分析三套在美国广受欢迎的汉语教材在教学次序、语法解释及练习活动上对两种 “过” 的处理,最后以样例示范形式提出针对 “过” 的对教材编写及教学活动的建议。